MX2009010951A - Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. - Google Patents
Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c.Info
- Publication number
- MX2009010951A MX2009010951A MX2009010951A MX2009010951A MX2009010951A MX 2009010951 A MX2009010951 A MX 2009010951A MX 2009010951 A MX2009010951 A MX 2009010951A MX 2009010951 A MX2009010951 A MX 2009010951A MX 2009010951 A MX2009010951 A MX 2009010951A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- pyrazole
- amido
- inhibitors
- protein kinase
- Prior art date
Links
- 102000003923 Protein Kinase C Human genes 0.000 title 1
- 108090000315 Protein Kinase C Proteins 0.000 title 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91146207P | 2007-04-12 | 2007-04-12 | |
| US3551908P | 2008-03-11 | 2008-03-11 | |
| US4011508P | 2008-03-27 | 2008-03-27 | |
| PCT/IB2008/000862 WO2008125945A2 (en) | 2007-04-12 | 2008-04-10 | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010951A true MX2009010951A (es) | 2009-10-29 |
Family
ID=39764996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010951A MX2009010951A (es) | 2007-04-12 | 2008-04-10 | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8114871B2 (enExample) |
| EP (1) | EP2195321B1 (enExample) |
| JP (1) | JP5404601B2 (enExample) |
| KR (1) | KR101113387B1 (enExample) |
| CN (3) | CN101675052A (enExample) |
| AU (1) | AU2008237660B2 (enExample) |
| CA (1) | CA2683695C (enExample) |
| HK (1) | HK1207067A1 (enExample) |
| IL (1) | IL201104A (enExample) |
| MX (1) | MX2009010951A (enExample) |
| WO (1) | WO2008125945A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101675052A (zh) | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| WO2011044264A2 (en) * | 2009-10-06 | 2011-04-14 | Afraxis, Inc. | Pyrrolopyrazoles for treating cns disorders |
| ES2444543T3 (es) * | 2009-11-10 | 2014-02-25 | Pfizer Inc | Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EP2621493B1 (en) | 2010-09-30 | 2016-08-17 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| CN104774205A (zh) | 2010-10-29 | 2015-07-15 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| BR112013020510A2 (pt) | 2011-02-11 | 2016-07-12 | Glaxosmithkline Ip Dev Ltd | inibidores de catepsina c |
| JP5657174B2 (ja) | 2011-04-22 | 2015-01-21 | ファイザー・インク | アセチルＣｏＡカルボキシラーゼ阻害剤として使用するためのピラゾロスピロケトン誘導体 |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| ES2882807T3 (es) * | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2015263884B2 (en) | 2014-05-23 | 2019-11-14 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
| AU2015337607B2 (en) * | 2014-10-31 | 2020-04-09 | Ube Corporation | Substituted dihydropyrrolopyrazole compound |
| EA201790868A1 (ru) * | 2014-11-21 | 2017-10-31 | Эли Лилли Энд Компани | 1,2-бензотиазольные соединения для лечения почечного расстройства |
| EP3236959B1 (en) * | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2016160617A2 (en) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| RU2765718C1 (ru) * | 2015-06-15 | 2022-02-02 | Убе Индастриз, Лтд. | Замещенное производное дигидропирролопиразола |
| JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| KR20180094906A (ko) | 2015-11-20 | 2018-08-24 | 밍사이트 파마슈티칼스, 인크. | 자가면역 질환의 치료 |
| CN115381832A (zh) | 2016-07-14 | 2022-11-25 | 深圳明赛瑞霖药业有限公司 | 癌症的治疗 |
| CN112367991A (zh) | 2018-06-25 | 2021-02-12 | 达纳-法伯癌症研究所股份有限公司 | Taire家族激酶抑制剂及其用途 |
| JP7530297B2 (ja) | 2018-11-14 | 2024-08-07 | Ｕｂｅ株式会社 | ジヒドロピロロピラゾール誘導体 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN119684220A (zh) * | 2024-12-13 | 2025-03-25 | 江苏宝众宝达药业股份有限公司 | 一种(2r,5r)-1,2,5-三甲基哌嗪的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ524475A (en) * | 2000-08-10 | 2004-11-26 | Pharmacia Italia S | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| US20070037790A1 (en) * | 2003-03-11 | 2007-02-15 | Francesca Abrate | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2007506787A (ja) * | 2003-09-23 | 2007-03-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体 |
| JP4250195B2 (ja) * | 2005-01-10 | 2009-04-08 | ファイザー・インク | ピロロピラゾール類、強力なキナーゼ阻害剤 |
| CN101675052A (zh) | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
-
2008
- 2008-04-10 CN CN200880014779A patent/CN101675052A/zh active Pending
- 2008-04-10 EP EP08737405.4A patent/EP2195321B1/en not_active Not-in-force
- 2008-04-10 MX MX2009010951A patent/MX2009010951A/es active IP Right Grant
- 2008-04-10 CN CN201410533053.XA patent/CN104370914B/zh not_active Expired - Fee Related
- 2008-04-10 US US12/532,051 patent/US8114871B2/en not_active Expired - Fee Related
- 2008-04-10 KR KR1020097021175A patent/KR101113387B1/ko not_active Expired - Fee Related
- 2008-04-10 AU AU2008237660A patent/AU2008237660B2/en not_active Ceased
- 2008-04-10 CA CA2683695A patent/CA2683695C/en active Active
- 2008-04-10 WO PCT/IB2008/000862 patent/WO2008125945A2/en not_active Ceased
- 2008-04-10 JP JP2010502601A patent/JP5404601B2/ja not_active Expired - Fee Related
- 2008-04-10 CN CN201410533054.4A patent/CN104356136A/zh active Pending
-
2009
- 2009-09-22 IL IL201104A patent/IL201104A/en active IP Right Grant
-
2010
- 2010-06-09 HK HK15107642.0A patent/HK1207067A1/xx unknown
-
2012
- 2012-01-06 US US13/345,528 patent/US8999981B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008125945A3 (en) | 2009-03-12 |
| CA2683695A1 (en) | 2008-10-23 |
| HK1207068A1 (en) | 2016-01-22 |
| IL201104A0 (en) | 2010-05-17 |
| KR101113387B1 (ko) | 2012-04-23 |
| CA2683695C (en) | 2013-06-18 |
| CN104370914B (zh) | 2018-09-07 |
| US20100249128A1 (en) | 2010-09-30 |
| US20120108588A1 (en) | 2012-05-03 |
| EP2195321A2 (en) | 2010-06-16 |
| CN104370914A (zh) | 2015-02-25 |
| US8114871B2 (en) | 2012-02-14 |
| CN101675052A (zh) | 2010-03-17 |
| AU2008237660A1 (en) | 2008-10-23 |
| AU2008237660B2 (en) | 2011-12-22 |
| KR20090130039A (ko) | 2009-12-17 |
| HK1207067A1 (en) | 2016-01-22 |
| US8999981B2 (en) | 2015-04-07 |
| CN104356136A (zh) | 2015-02-18 |
| EP2195321B1 (en) | 2016-10-19 |
| IL201104A (en) | 2017-09-28 |
| JP5404601B2 (ja) | 2014-02-05 |
| JP2010523643A (ja) | 2010-07-15 |
| WO2008125945A2 (en) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010951A (es) | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. | |
| MX2009008546A (es) | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldehido como inhibidores de la proteina quinasa c. | |
| EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
| UA96618C2 (en) | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors | |
| WO2008010238A3 (en) | Antidiabetic azabicyclo [3. 1. 0] hexan compounds | |
| TW200612956A (en) | Dihydropteridinones for the treatment of cancer diseases | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| WO2007084391A3 (en) | Thiazole compounds as protein kinase b ( pkb) inhibitors | |
| GEP20125379B (en) | 2 -pyridine carboxamide derivatives as sodium channel modulators | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| WO2010066684A3 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| WO2009155527A3 (en) | Phosphatidylinositol 3 kinase inhibitors | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| WO2008002244A8 (en) | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) | |
| BRPI0411868B8 (pt) | derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| US20090275585A1 (en) | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | |
| WO2007022437A3 (en) | Therapeutic agents for the treatment of cancer and metabolic disorders | |
| BRPI0507375A (pt) | derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase | |
| WO2007024843A3 (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
| EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 | |
| MX2010013978A (es) | Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |